Safety and Pharmacokinetics of AZD9550, a GLP-1R/GCGR Dual Agonist, in a First-in-Human Study

被引：0
|
作者：
Sulentic, Petra
Will, Sarah
Daniels, Samuel
Genapathy, Sivaneswary
Naylor, Jacqueline
Barbour, April
Yu, Hongtao
Boca, Simina
Carlsson, Elin
Gopel, Sven
Hornigold, David
Oldham, Stephanie
Robertson, Darren
Jermutus, Lutz
Karimi, Mahssa
Hansen, Lars
机构：
来源：
OBESITY | 2024年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Poster-268
引用
收藏
页码：161 / 162
页数：2
相关论文
共 50 条
  • [1] Differential efficacy of a GLP-1R/GCGR dual agonist versus a GLP-1R agonist in diet-induced obese mice
    Valdecantos, M. P.
    Ruiz, L.
    Obregon, M. J.
    Dos Santos, A.
    Bednarek, M. A.
    Grimsby, J.
    Rondinone, C.
    Valverde, A. M.
    DIABETOLOGIA, 2018, 61 : S219 - S220
  • [2] Characterising the pharmacology of glucagon receptor agonism in a dual GCGR/GLP-1R agonist
    Kloeckener, T.
    Zimmermann, T.
    Haebel, P.
    Bajrami, B.
    Augustin, R.
    DIABETOLOGIA, 2024, 67 : S46 - S46
  • [3] Structural analysis of the dual agonism at GLP-1R and GCGR
    Li, Yang
    Zhou, Qingtong
    Dai, Antao
    Zhao, Fenghui
    Chang, Rulue
    Ying, Tianlei
    Wu, Beili
    Yang, Dehua
    Wang, Ming-Wei
    Cong, Zhaotong
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (33)
  • [4] Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
    Song, Nazi
    Xu, Hongjiao
    Liu, Jiahua
    Zhao, Qian
    Chen, Hui
    Yan, Zhibin
    Yang, Runling
    Luo, Zhiteng
    Liu, Qi
    Ouyang, Jianmei
    Wu, Shuohan
    Luo, Suijia
    Ye, Shuyin
    Lin, Runfeng
    Sun, Xi
    Xie, Junqiu
    Lan, Tian
    Wu, Zhongdao
    Wang, Rui
    Jiang, Xianxing
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (05) : 2443 - 2461
  • [5] Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
    Nazi Song
    Hongjiao Xu
    Jiahua Liu
    Qian Zhao
    Hui Chen
    Zhibin Yan
    Runling Yang
    Zhiteng Luo
    Qi Liu
    Jianmei Ouyang
    Shuohan Wu
    Suijia Luo
    Shuyin Ye
    Runfeng Lin
    Xi Sun
    Junqiu Xie
    Tian Lan
    Zhongdao Wu
    Rui Wang
    Xianxing Jiang
    Acta Pharmaceutica Sinica B, 2022, 12 (05) : 2443 - 2461
  • [6] The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
    Thomas, Leo
    Martel, Eric
    Rist, Wolfgang
    Uphues, Ingo
    Hamprecht, Dieter
    Neubauer, Heike
    Augustin, Robert
    DIABETES OBESITY & METABOLISM, 2024, 26 (06): : 2368 - 2378
  • [7] Differential efficacy of a GLP-1R/GCGR agonist versus a GLP-1R agonist in improving hepatic insulin sensitivity and reducing steatosis in obese mice
    Valdecantos, P.
    Ruiz-Canas, L.
    Rada, P.
    Gonzalez-Rodrignez, A.
    Konkar, A.
    Dos Santos, A.
    Bednarek, M.
    Grimsby, J.
    Rondinone, C.
    Valverde, A. M.
    DIABETOLOGIA, 2016, 59 : S374 - S374
  • [8] The Effect of Bispecific GLP-1R/GLP-2R Agonist Compared with Dual GLP-1R/GLP-2R Agonist and Dual GLP-1R/GIPR Agonist in Diet-Induced Obesity Mouse Model
    Oh, Timothy
    Yang, Sang-In
    Roh, Jaeil
    Sung, Jee Yoon
    DIABETES, 2023, 72
  • [9] Effect of GLP1R/GCGR Dual Agonist in Monkeys
    Lao, Julie
    Hansen, Barbara C.
    Dimarchi, Richard
    Pocai, Alessandro
    DIABETES, 2013, 62 : A257 - A257
  • [10] A Phase 1b/2a Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of PB-718, a GLP-1R/GCGR Dual Agonist in Subjects with Obesity
    Ding, Ke
    DIABETES, 2024, 73
12345